Trials / Unknown
UnknownNCT05810103
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of DP303c in patients with HER2-positive advanced solid tumors.
Detailed description
This is a multi-center, single-arm Phase I study to evaluate the pharmacokinetic profile, safety, and initial efficacy of DP303c in patients with HER2-positive advanced solid tumors. Patients will be treated with DP303c injection at 3.0 mg/kg every 3 weeks. Patients will receive DP303c until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DP303c | DP303c injection, 3.0 mg/kg, every 3 weeks. |
Timeline
- Start date
- 2023-04-06
- Primary completion
- 2023-12-23
- Completion
- 2024-03-23
- First posted
- 2023-04-12
- Last updated
- 2023-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05810103. Inclusion in this directory is not an endorsement.